FormuMax

Executive Summary

FormuMax Scientific is a privately held specialty drug delivery company headquartered in Sunnyvale, California, founded in 2001. The company focuses on developing formulation and drug delivery technologies leveraging liposomes, lipospheres, micellar systems, and other nano-enabled platforms. FormuMax operates a dual business model: it provides contract formulation development services to pharmaceutical and biotech clients, and it supplies pre-formed liposome research reagents and kits to academic and commercial laboratories. With over two decades of experience in lipid-based delivery systems, FormuMax has established a niche in enabling bioavailability enhancement, targeted delivery, and controlled release of therapeutic agents. Despite its long tenure in the drug delivery space, FormuMax remains a small private entity with limited public information on revenue, funding, or clinical partnerships. The company's growth is likely tied to the increasing demand for advanced delivery systems, particularly for RNA therapeutics, vaccines, and oncology drugs. However, without disclosed milestones or pipeline developments, its commercial traction and competitive positioning are difficult to assess. The absence of disclosed recent funding rounds or strategic alliances suggests a conservative growth trajectory. FormuMax's primary value may reside in its proprietary encapsulation technologies and its established reputation as a reliable CDMO for liposomal formulations.

Upcoming Catalysts (preview)

• Q2 2026New Liposome CDMO Contract with Emerging Biotech60% success
• Q4 2026Expansion of Research Reagent Product Line50% success
• Q3 2026Strategic Partnership for LNP (Lipid Nanoparticle) Technology40% success